Neupro may reduce cognitive dysfunction among patients with Alzheimer’s disease

The dopaminergic agonist Neupro appeared to improve frontal cognitive functions and activities of daily living among patients with mild to moderate Alzheimer’s disease, according to study results published in JAMA Network Open. “Some early attempts have been carried out using dopaminergic drugs, such as L-dopa or selegiline, in samples of patients with Alzheimer’s disease atContinue reading “Neupro may reduce cognitive dysfunction among patients with Alzheimer’s disease”